6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
enterocolitis	JJ	enterocolitis	enterocolitis	enterocol	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Other	JJ	other	other	other	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
manifestations	NNS	manifestations	manifestation	manifest	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Bristol	NNP	bristol	bristol	bristol	N	O
-	:	-	-	-	N	O
Myers	NNS	myers	myers	myer	N	O
Squibb	VBP	squibb	squibb	squibb	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
721	CD	721	721	721	N	O
-	:	-	-	-	N	O
5072	CD	5072	5072	5072	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
cannot	JJ	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
or	CC	or	or	or	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
therapeutics	NNS	therapeutics	therapeutic	therapeut	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
excluded	VBD	excluded	excluded	exclud	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
autoimmune	JJ	autoimmune	autoimmune	autoimmun	N	O
disease	NN	disease	disease	diseas	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
systemic	JJ	systemic	systemic	system	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
for	IN	for	for	for	N	O
organ	JJ	organ	organ	organ	N	O
transplantation	NN	transplantation	transplantation	transplant	N	O
.	.	.	.	.	N	O

Exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
YERVOY	VB	yervoy	yervoy	yervoy	N	O
3	CD	3	3	3	N	O
mg	NNS	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
for	IN	for	for	for	N	O
4	CD	4	4	4	N	O
doses	NNS	doses	dos	dose	N	O
given	VBN	given	given	given	N	O
by	IN	by	by	by	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
in	IN	in	in	in	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
unresectable	JJ	unresectable	unresectable	unresect	N	O
or	CC	or	or	or	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	VB	blind	blind	blind	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

One	CD	one	one	one	N	O
hundred	VBD	hundred	hundred	hundr	N	O
thirty	SYM	thirty	thirty	thirti	N	O
-	:	-	-	-	N	O
one	CD	one	one	one	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
57	CD	57	57	57	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
60%	CD	60%	60%	60%	N	O
male	NN	male	male	male	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
,	,	,	,	,	N	O
380	CD	380	380	380	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
56	CD	56	56	56	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
61%	CD	61%	61%	61%	N	O
male	NN	male	male	male	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
investigational	JJ	investigational	investigational	investig	N	O
gp100	NN	gp100	gp100	gp100	N	O
peptide	NN	peptide	peptide	peptid	N	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
(	(	(	(	(	N	O
gp100	NN	gp100	gp100	gp100	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
132	CD	132	132	132	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
57	CD	57	57	57	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
54%	CD	54%	54%	54%	N	O
male	NN	male	male	male	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
gp100	JJ	gp100	gp100	gp100	N	O
peptide	JJ	peptide	peptide	peptid	N	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
4	CD	4	4	4	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
doses	NNS	doses	dos	dose	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

YERVOY	NN	yervoy	yervoy	yervoy	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
at	IN	at	at	at	N	O
3	CD	3	3	3	N	O
mg	NNS	mg	mg	mg	N	O
kg	NNS	kg	kg	kg	N	O
were	VBD	were	were	were	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
presents	NNS	presents	present	present	N	O
selected	VBN	selected	selected	select	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
containing	NN	containing	containing	contain	N	O
arms	NNS	arms	arm	arm	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
increased	VBD	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
gp100	NN	gp100	gp100	gp100	N	O
arm	NN	arm	arm	arm	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
grade	NN	grade	grade	grade	N	O
events	NNS	events	event	event	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
incidence	NN	incidence	incidence	incid	N	O
over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Selected	VBN	selected	selected	select	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

a	DT	a	a	a	N	O
Incidences	NNP	incidences	incidence	incid	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
table	NN	table	table	tabl	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
.	.	.	.	.	N	O

Percentage	NN	percentage	percentage	percentag	N	O

(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patientsa	NNP	patientsa	patientsa	patientsa	N	O

YERVOY3	NNP	yervoy3	yervoy3	yervoy3	N	O
mg	VBD	mg	mg	mg	N	O
kgn	$	kgn	kgn	kgn	N	O
131	CD	131	131	131	N	O
YERVOY3	NNP	yervoy3	yervoy3	yervoy3	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
gp100n	VBD	gp100n	gp100n	gp100n	N	O
380	CD	380	380	380	N	O
gp100n	NN	gp100n	gp100n	gp100n	N	O
132	CD	132	132	132	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
32	CD	32	32	32	N	O
5	CD	5	5	5	N	O
37	CD	37	37	37	N	O
4	CD	4	4	4	N	O
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O

Colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
8	CD	8	8	8	N	O
5	CD	5	5	5	N	O
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
31	CD	31	31	31	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
1	CD	1	1	1	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
29	CD	29	29	29	N	O
2	CD	2	2	2	N	O
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
41	CD	41	41	41	N	O
7	CD	7	7	7	N	O
34	CD	34	34	34	N	O
5	CD	5	5	5	N	O
31	CD	31	31	31	N	O
3	CD	3	3	3	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
per	IN	per	per	per	N	O
-	:	-	-	-	N	O
patient	NN	patient	patient	patient	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
from	IN	from	from	from	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	B-Severity
to	TO	to	to	to	N	O
Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
Adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

a	DT	a	a	a	N	O
Including	NNP	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Including	NNP	including	including	includ	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Underlying	VBG	underlying	underlying	underli	N	O
etiology	NN	etiology	etiology	etiolog	N	O
not	RB	not	not	not	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Percentage	NN	percentage	percentage	percentag	N	O

(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O

YERVOY3	NNP	yervoy3	yervoy3	yervoy3	N	O
mg	VBD	mg	mg	mg	N	O
kgn	$	kgn	kgn	kgn	N	O
131	CD	131	131	131	N	O
YERVOY3	NNP	yervoy3	yervoy3	yervoy3	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
gp100n	VBD	gp100n	gp100n	gp100n	N	O
380	CD	380	380	380	N	O

Any	DT	any	any	ani	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
15	CD	15	15	15	N	O
12	CD	12	12	12	N	O

Enterocolitisa	NNP	enterocolitisa	enterocolitisa	enterocolitisa	N	B-AdverseReaction
,	,	,	,	,	N	O
b	VBD	b	b	b	N	O
7	CD	7	7	7	N	O
7	CD	7	7	7	N	O

Hepatotoxicitya	NNP	hepatotoxicitya	hepatotoxicitya	hepatotoxicitya	N	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Dermatitisa	NNP	dermatitisa	dermatitisa	dermatitisa	N	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Neuropathya	NNP	neuropathya	neuropathya	neuropathya	N	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Endocrinopathy	JJ	endocrinopathy	endocrinopathy	endocrinopathi	N	B-AdverseReaction
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O

Hypopituitarism	NNP	hypopituitarism	hypopituitarism	hypopituitar	Y	B-AdverseReaction
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O

Adrenal	NNP	adrenal	adrenal	adren	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Other	JJ	other	other	other	N	O

Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Meningitis	NNP	meningitis	meningitis	mening	Y	B-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Nephritis	RB	nephritis	nephritis	nephriti	Y	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Eosinophiliac	NNP	eosinophiliac	eosinophiliac	eosinophiliac	N	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Pericarditisa	NNP	pericarditisa	pericarditisa	pericarditisa	N	B-AdverseReaction
,	,	,	,	,	N	O
c	VBD	c	c	c	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
that	WDT	that	that	that	N	O
utilized	VBD	utilized	utilized	util	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
0.3	CD	0.3	0.3	0.3	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
unless	IN	unless	unless	unless	N	O
otherwise	RB	otherwise	otherwise	otherwis	N	O
noted	VBN	noted	noted	note	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
large	JJ	large	large	larg	N	B-AdverseReaction
intestinal	JJ	intestinal	intestinal	intestin	N	I-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction
,	,	,	,	,	N	O
esophagitis	NN	esophagitis	esophagitis	esophag	Y	B-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O

on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
entire	JJ	entire	entire	entir	N	O
clinical	JJ	clinical	clinical	clinic	N	O
program	NN	program	program	program	N	O
for	IN	for	for	for	N	O
melanoma	NN	melanoma	melanoma	melanoma	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
appear	VBP	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
dose	JJ	dose	dose	dose	N	O
dependent	NN	dependent	dependent	depend	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
postapproval	JJ	postapproval	postapproval	postapprov	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Drug	NNP	drug	drug	drug	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
eosinophilia	NNS	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
systemic	JJ	systemic	systemic	system	N	I-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
)	)	)	)	)	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
of	IN	of	of	of	N	O
1024	CD	1024	1024	1024	N	O
evaluable	JJ	evaluable	evaluable	evalu	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
electrochemiluminescent	NN	electrochemiluminescent	electrochemiluminescent	electrochemiluminesc	N	O
(	(	(	(	(	N	O
ECL	NNP	ecl	ecl	ecl	N	O
)	)	)	)	)	N	O
based	VBN	based	based	base	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
assay	NN	assay	assay	assay	N	O
has	VBZ	has	ha	ha	N	O
substantial	JJ	substantial	substantial	substanti	N	O
limitations	NNS	limitations	limitation	limit	N	O
in	IN	in	in	in	N	O
detecting	VBG	detecting	detecting	detect	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
.	.	.	.	.	N	O

Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	VBD	related	related	relat	N	I-AdverseReaction
or	CC	or	or	or	N	O
peri	JJ	peri	peri	peri	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infusional	JJ	infusional	infusional	infusion	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
or	CC	or	or	or	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	B-Negation
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
11	CD	11	11	11	N	O
patients	NNS	patients	patient	patient	N	O
nor	CC	nor	nor	nor	N	O
were	VBD	were	were	were	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
detected	VBN	detected	detected	detect	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
trough	JJ	trough	trough	trough	N	O
levels	NNS	levels	level	level	N	O
of	IN	of	of	of	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
interfere	NN	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
ECL	NNP	ecl	ecl	ecl	N	O
assay	NN	assay	assay	assay	N	O
results	NNS	results	result	result	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
subset	NN	subset	subset	subset	N	O
analysis	NN	analysis	analysis	analysi	N	O
was	VBD	was	wa	wa	N	O
performed	VBN	performed	performed	perform	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
cohort	NN	cohort	cohort	cohort	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
lowest	JJS	lowest	lowest	lowest	N	O
trough	NN	trough	trough	trough	N	O
levels	NNS	levels	level	level	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
analysis	NN	analysis	analysis	analysi	N	O
,	,	,	,	,	N	O
6.9%	CD	6.9%	6.9%	6.9%	N	O
of	IN	of	of	of	N	O
58	CD	58	58	58	N	O
evaluable	JJ	evaluable	evaluable	evalu	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
0.3	CD	0.3	0.3	0.3	N	O
mg	NNS	mg	mg	mg	N	O
kg	VBD	kg	kg	kg	N	O
dose	RB	dose	dose	dose	N	O
,	,	,	,	,	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
binding	VBG	binding	binding	bind	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
ipilimumab	NN	ipilimumab	ipilimumab	ipilimumab	N	O
.	.	.	.	.	N	O

Immunogenicity	NNP	immunogenicity	immunogenicity	immunogen	N	O
assay	VBP	assay	assay	assay	N	O
results	NNS	results	result	result	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
YERVOY	VB	yervoy	yervoy	yervoy	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
ADVERSE	NNP	adverse	adverse	advers	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
\n\n	VBP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
ADVERSE	NNP	adverse	adverse	advers	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
activation	NN	activation	activation	activ	N	O
and	CC	and	and	and	N	O
proliferation	NN	proliferation	proliferation	prolifer	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
involve	VB	involve	involve	involv	N	O
any	DT	any	any	ani	N	O
organ	JJ	organ	organ	organ	N	O
system	NN	system	system	system	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
severe	JJ	severe	severe	sever	N	B-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
are	VBP	are	are	are	N	O
enterocolitis	RB	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
toxic	NN	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
initially	RB	initially	initially	initi	N	O
manifested	VBD	manifested	manifested	manifest	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
minority	NN	minority	minority	minor	N	O
occurred	VBD	occurred	occurred	occur	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

Assess	NN	assess	ass	assess	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
endocrinopathy	JJ	endocrinopathy	endocrinopathy	endocrinopathi	N	O
and	CC	and	and	and	N	O
evaluate	JJ	evaluate	evaluate	evalu	N	O
clinical	JJ	clinical	clinical	clinic	N	O
chemistries	NNS	chemistries	chemistry	chemistri	N	O
including	VBG	including	including	includ	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
ADVERSE	NNP	adverse	adverse	advers	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

YERVOY	NN	yervoy	yervoy	yervoy	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
activation	NN	activation	activation	activ	N	O
and	CC	and	and	and	N	O
proliferation	NN	proliferation	proliferation	prolifer	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
may	MD	may	may	may	N	B-Factor
involve	VB	involve	involve	involv	N	O
any	DT	any	any	ani	N	O
organ	JJ	organ	organ	organ	N	O
system	NN	system	system	system	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
severe	JJ	severe	severe	sever	N	B-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
are	VBP	are	are	are	N	O
enterocolitis	RB	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
toxic	NN	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
initially	RB	initially	initially	initi	N	O
manifested	VBD	manifested	manifested	manifest	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
minority	NN	minority	minority	minor	N	O
occurred	VBD	occurred	occurred	occur	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Assess	NNP	assess	ass	assess	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
endocrinopathy	JJ	endocrinopathy	endocrinopathy	endocrinopathi	N	O
and	CC	and	and	and	N	O
evaluate	JJ	evaluate	evaluate	evalu	N	O
clinical	JJ	clinical	clinical	clinic	N	O
chemistries	NNS	chemistries	chemistry	chemistri	N	O
including	VBG	including	including	includ	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

YERVOY	NN	yervoy	yervoy	yervoy	N	O
can	MD	can	can	can	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
T	NNP	t	t	t	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
activation	NN	activation	activation	activ	N	O
and	CC	and	and	and	N	O
proliferation	NN	proliferation	proliferation	prolifer	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
dose	NN	dose	dose	dose	N	O
for	IN	for	for	for	N	O
moderate	JJ	moderate	moderate	moder	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	JJ	mediated	mediated	mediat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
until	IN	until	until	until	N	O
return	NN	return	return	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
improvement	NN	improvement	improvement	improv	N	O
to	TO	to	to	to	N	O
mild	VB	mild	mild	mild	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
receiving	VBG	receiving	receiving	receiv	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
7.5	CD	7.5	7.5	7.5	N	O
mg	JJ	mg	mg	mg	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
systemic	JJ	systemic	systemic	system	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
recurring	VBG	recurring	recurring	recur	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
:	:	:	:	:	N	O
Evaluate	NNP	evaluate	evaluate	evalu	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

?	.	?	?	?	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
chemistries	NNS	chemistries	chemistry	chemistri	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Evaluate	NN	evaluate	evaluate	evalu	N	O
at	IN	at	at	at	N	O
each	DT	each	each	each	N	O
visit	NN	visit	visit	visit	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	O
.	.	.	.	.	N	O

Institute	NNP	institute	institute	institut	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Immune	NN	immune	immune	immun	N	O

-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
severe	RB	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
(	(	(	(	(	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
of	IN	of	of	of	N	O
7	CD	7	7	7	N	B-Severity
or	CC	or	or	or	N	I-Severity
more	JJR	more	more	more	N	I-Severity
stools	NNS	stools	stool	stool	N	I-Severity
above	IN	above	above	abov	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
ileus	NN	ileus	ileus	ileu	Y	B-AdverseReaction
,	,	,	,	,	N	O
peritoneal	JJ	peritoneal	peritoneal	periton	N	B-AdverseReaction
signs	NNS	signs	sign	sign	N	I-AdverseReaction
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
)	)	)	)	)	N	O
immune	NN	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
34	CD	34	34	34	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
(	(	(	(	(	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
with	IN	with	with	with	N	O
up	IN	up	up	up	N	B-Severity
to	TO	to	to	to	N	I-Severity
6	CD	6	6	6	N	I-Severity
stools	NNS	stools	stool	stool	N	I-Severity
above	IN	above	above	abov	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
mucus	NN	mucus	mucus	mucu	N	B-AdverseReaction
or	CC	or	or	or	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
stool	NN	stool	stool	stool	N	I-AdverseReaction
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
)	)	)	)	)	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
511	CD	511	511	511	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
died	VBD	died	died	die	N	B-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
complications	NNS	complications	complication	complic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
hospitalized	VBN	hospitalized	hospitalized	hospit	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	B-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
was	VBD	was	wa	wa	N	O
7.4	CD	7.4	7.4	7.4	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
1.6	CD	1.6	1.6	1.6	N	O
-	:	-	-	-	N	O
13.4	CD	13.4	13.4	13.4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
6.3	CD	6.3	6.3	6.3	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
0.3	CD	0.3	0.3	0.3	N	O
-	:	-	-	-	N	O
18.9	CD	18.9	18.9	18.9	N	O
)	)	)	)	)	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Twenty	NNP	twenty	twenty	twenti	N	O
-	:	-	-	-	N	O
nine	CD	nine	nine	nine	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
85%	CD	85%	85%	85%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
(	(	(	(	(	N	O
40	CD	40	40	40	N	O
mg	RB	mg	mg	mg	N	O
prednisone	JJ	prednisone	prednisone	prednison	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
80	CD	80	80	80	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
;	:	;	;	;	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
2.3	CD	2.3	2.3	2.3	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
ranging	VBG	ranging	ranging	rang	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
13.9	CD	13.9	13.9	13.9	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
taper	NN	taper	taper	taper	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
28	CD	28	28	28	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
46%	CD	46%	46%	46%	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
29%	CD	29%	29%	29%	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
40	CD	40	40	40	N	O
mg	NNS	mg	mg	mg	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
5.1	CD	5.1	5.1	5.1	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
25%	CD	25%	25%	25%	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
days	NNS	days	day	day	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
corticosteroid	VB	corticosteroid	corticosteroid	corticosteroid	N	O
taper	NN	taper	taper	taper	N	O
.	.	.	.	.	N	O

Infliximab	NNP	infliximab	infliximab	infliximab	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
62	CD	62	62	62	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	I-AdverseReaction
following	VBG	following	following	follow	N	O
inadequate	JJ	inadequate	inadequate	inadequ	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
34	CD	34	34	34	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
74%	CD	74%	74%	74%	N	O
experienced	VBD	experienced	experienced	experienc	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
experienced	VBD	experienced	experienced	experienc	N	O
improvement	NN	improvement	improvement	improv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
24%	CD	24%	24%	24%	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
improve	VB	improve	improve	improv	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
28	CD	28	28	28	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
79%	CD	79%	79%	79%	N	O
experienced	VBD	experienced	experienced	experienc	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
11%	CD	11%	11%	11%	N	O
improved	VBN	improved	improved	improv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
11%	CD	11%	11%	11%	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
improve	VB	improve	improve	improv	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
mucus	NN	mucus	mucus	mucu	N	O
or	CC	or	or	or	N	O
blood	NN	blood	blood	blood	N	O
in	IN	in	in	in	N	O
stool	NN	stool	stool	stool	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
fever	NN	fever	fever	fever	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
of	IN	of	of	of	N	O
bowel	NN	bowel	bowel	bowel	N	O
perforation	NN	perforation	perforation	perfor	Y	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
peritoneal	JJ	peritoneal	peritoneal	periton	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
ileus	NN	ileus	ileus	ileu	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
rule	NN	rule	rule	rule	N	O
out	IN	out	out	out	N	O
infectious	JJ	infectious	infectious	infecti	N	O
etiologies	NNS	etiologies	etiology	etiolog	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
endoscopic	JJ	endoscopic	endoscopic	endoscop	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
for	IN	for	for	for	N	O
persistent	NN	persistent	persistent	persist	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
.	.	.	.	.	N	O

Upon	IN	upon	upon	upon	N	O
improvement	NN	improvement	improvement	improv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
,	,	,	,	,	N	O
initiate	JJ	initiate	initiate	initi	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
taper	NN	taper	taper	taper	N	O
and	CC	and	and	and	N	O
continue	VB	continue	continue	continu	N	O
to	TO	to	to	to	N	O
taper	VB	taper	taper	taper	N	O
over	RP	over	over	over	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
rapid	JJ	rapid	rapid	rapid	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
tapering	VBG	tapering	tapering	taper	N	O
resulted	VBN	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
dosing	VBG	dosing	dosing	dose	N	O
for	IN	for	for	for	N	O
moderate	JJ	moderate	moderate	moder	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	O
;	:	;	;	;	N	O
administer	CC	administer	administer	administ	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheal	NN	diarrheal	diarrheal	diarrheal	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
persistent	JJ	persistent	persistent	persist	N	O
for	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
initiate	VBP	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
0.5	CD	0.5	0.5	0.5	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.2	CD	5.2	5.2	5.2	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
severe	RB	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
of	IN	of	of	of	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
or	CC	or	or	or	N	O
total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
and	CC	and	and	and	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
manifested	VBN	manifested	manifested	manifest	N	O
by	IN	by	by	by	N	O
liver	NN	liver	liver	liver	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
of	IN	of	of	of	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2.5	CD	2.5	2.5	2.5	N	B-Severity
times	NNS	times	time	time	N	I-Severity
but	CC	but	but	but	N	I-Severity
not	RB	not	not	not	N	I-Severity
more	JJR	more	more	more	N	I-Severity
than	IN	than	than	than	N	I-Severity
5	CD	5	5	5	N	I-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
or	CC	or	or	or	N	O
total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
of	IN	of	of	of	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1.5	CD	1.5	1.5	1.5	N	B-Severity
times	NNS	times	time	time	N	I-Severity
but	CC	but	but	but	N	I-Severity
not	RB	not	not	not	N	I-Severity
more	JJR	more	more	more	N	I-Severity
than	IN	than	than	than	N	I-Severity
3	CD	3	3	3	N	I-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
underlying	VBG	underlying	underlying	underli	N	O
pathology	NN	pathology	pathology	patholog	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
ascertained	VBN	ascertained	ascertained	ascertain	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
but	CC	but	but	but	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
instances	NNS	instances	instance	instanc	N	O
included	VBD	included	included	includ	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
numbers	NNS	numbers	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
biopsy	JJ	biopsy	biopsy	biopsi	Y	O
-	:	-	-	-	N	O
proven	RB	proven	proven	proven	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
to	TO	to	to	to	N	O
characterize	VB	characterize	characterize	character	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
event	NN	event	event	event	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
(	(	(	(	(	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
and	CC	and	and	and	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
levels	NNS	levels	level	level	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
assess	JJ	assess	ass	assess	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
,	,	,	,	,	N	O
rule	NN	rule	rule	rule	N	O
out	RB	out	out	out	N	O
infectious	JJ	infectious	infectious	infecti	N	O
or	CC	or	or	or	N	O
malignant	JJ	malignant	malignant	malign	N	O
causes	NNS	causes	cause	caus	N	O
and	CC	and	and	and	N	O
increase	VB	increase	increase	increas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
test	NN	test	test	test	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
until	IN	until	until	until	N	O
resolution	NN	resolution	resolution	resolut	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
and	CC	and	and	and	N	O
administer	NN	administer	administer	administ	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
liver	NN	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
show	VBP	show	show	show	N	O
sustained	JJ	sustained	sustained	sustain	N	O
improvement	NN	improvement	improvement	improv	N	O
or	CC	or	or	or	N	O
return	NN	return	return	return	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
initiate	VB	initiate	initiate	initi	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
tapering	NN	tapering	tapering	taper	N	O
and	CC	and	and	and	N	O
continue	VB	continue	continue	continu	N	O
to	TO	to	to	to	N	O
taper	VB	taper	taper	taper	N	O
over	IN	over	over	over	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
for	IN	for	for	for	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
,	,	,	,	,	N	O
mycophenolate	NN	mycophenolate	mycophenolate	mycophenol	N	O
treatment	NN	treatment	treatment	treatment	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
administered	VBN	administered	administered	administ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
persistent	VBN	persistent	persistent	persist	N	O
severe	JJ	severe	severe	sever	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
despite	IN	despite	despite	despit	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

Concurrent	JJ	concurrent	concurrent	concurr	N	O
Administration	NNP	administration	administration	administr	N	O
with	IN	with	with	with	N	O
Vemurafenib	NNP	vemurafenib	vemurafenib	vemurafenib	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
finding	VBG	finding	finding	find	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
Grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
mg	RB	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
vemurafenib	NN	vemurafenib	vemurafenib	vemurafenib	N	O
(	(	(	(	(	N	O
960	CD	960	960	960	N	O
mg	NN	mg	mg	mg	N	O
BID	NNP	bid	bid	bid	N	O
or	CC	or	or	or	N	O
720	CD	720	720	720	N	O
mg	NNS	mg	mg	mg	N	O
BID	NNP	bid	bid	bid	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Dermatitis	NNP	dermatitis	dermatitis	dermat	Y	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
severe	RB	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
(	(	(	(	(	N	O
eg	JJ	eg	eg	eg	N	O
,	,	,	,	,	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
full	JJ	full	full	full	N	O
thickness	NN	thickness	thickness	thick	N	O
dermal	JJ	dermal	dermal	dermal	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
necrotic	JJ	necrotic	necrotic	necrot	N	I-AdverseReaction
,	,	,	,	,	N	O
bullous	JJ	bullous	bullous	bullou	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	I-AdverseReaction
manifestations	NNS	manifestations	manifestation	manifest	N	I-AdverseReaction
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
5	CD	5	5	5	N	I-Severity
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
patient	NN	patient	patient	patient	N	O
died	VBD	died	died	die	N	B-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
toxic	NN	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
additional	JJ	additional	additional	addit	N	O
patient	NN	patient	patient	patient	N	O
required	VBN	required	required	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
)	)	)	)	)	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
3.1	CD	3.1	3.1	3.1	N	O
weeks	NNS	weeks	week	week	N	O
and	CC	and	and	and	N	O
ranged	VBD	ranged	ranged	rang	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
17.3	CD	17.3	17.3	17.3	N	O
weeks	NNS	weeks	week	week	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

Seven	NNP	seven	seven	seven	N	O
(	(	(	(	(	N	O
54%	CD	54%	54%	54%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	B-Severity
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
received	VBD	received	received	receiv	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
(	(	(	(	(	N	O
median	JJ	median	median	median	N	O
dose	NN	dose	dose	dose	N	O
60	CD	60	60	60	N	O
mg	NN	mg	mg	mg	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
day	NN	day	day	day	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
14.9	CD	14.9	14.9	14.9	N	O
weeks	NNS	weeks	week	week	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
taper	NN	taper	taper	taper	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
7	CD	7	7	7	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
had	VBD	had	had	had	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
;	:	;	;	;	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
resolution	NN	resolution	resolution	resolut	N	O
ranged	VBD	ranged	ranged	rang	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
15.6	CD	15.6	15.6	15.6	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
63	CD	63	63	63	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
40%	CD	40%	40%	40%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
(	(	(	(	(	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
median	NN	median	median	median	N	O
of	IN	of	of	of	N	O
2.1	CD	2.1	2.1	2.1	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
only	RB	only	only	onli	N	O
topical	JJ	topical	topical	topic	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
49%	CD	49%	49%	49%	N	O
)	)	)	)	)	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
receive	VB	receive	receive	receiv	N	O
systemic	NN	systemic	systemic	system	N	O
or	CC	or	or	or	N	O
topical	JJ	topical	topical	topic	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Forty	NNP	forty	forty	forti	N	O
-	:	-	-	-	N	O
four	CD	four	four	four	N	O
(	(	(	(	(	N	O
70%	CD	70%	70%	70%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
improved	VBN	improved	improved	improv	N	O
to	TO	to	to	to	N	O
mild	VB	mild	mild	mild	N	O
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	O
reported	VBN	reported	reported	report	N	O
improvement	NN	improvement	improvement	improv	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
rash	NN	rash	rash	rash	Y	O
and	CC	and	and	and	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	O
.	.	.	.	.	N	O

Unless	IN	unless	unless	unless	N	O
an	DT	an	an	an	N	O
alternate	NN	alternate	alternate	altern	N	O
etiology	NN	etiology	etiology	etiolog	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
,	,	,	,	,	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Stevens	NNP	stevens	stevens	steven	N	O
-	:	-	-	-	N	O
Johnson	NNP	johnson	johnson	johnson	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	O
epidermal	JJ	epidermal	epidermal	epiderm	N	O
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
full	JJ	full	full	full	N	O
thickness	NN	thickness	thickness	thick	N	O
dermal	JJ	dermal	dermal	dermal	N	O
ulceration	NN	ulceration	ulceration	ulcer	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
necrotic	JJ	necrotic	necrotic	necrot	N	O
,	,	,	,	,	N	O
bullous	JJ	bullous	bullous	bullou	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
is	VBZ	is	is	is	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
tapering	NN	tapering	tapering	taper	N	O
should	MD	should	should	should	N	O
occur	VB	occur	occur	occur	N	O
over	IN	over	over	over	N	O
a	DT	a	a	a	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
dosing	VBG	dosing	dosing	dose	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

For	IN	for	for	for	N	O
mild	NN	mild	mild	mild	N	O
to	TO	to	to	to	N	O
moderate	VB	moderate	moderate	moder	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
localized	JJ	localized	localized	local	N	O
rash	NN	rash	rash	rash	Y	O
and	CC	and	and	and	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	O
,	,	,	,	,	N	O
treat	NN	treat	treat	treat	N	O
symptomatically	RB	symptomatically	symptomatically	symptomat	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
topical	JJ	topical	topical	topic	N	O
or	CC	or	or	or	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
if	IN	if	if	if	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
improvement	NN	improvement	improvement	improv	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
)	)	)	)	)	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
,	,	,	,	,	N	O
myasthenia	NN	myasthenia	myasthenia	myasthenia	Y	B-AdverseReaction
gravis	NN	gravis	gravis	gravi	N	I-AdverseReaction
and	CC	and	and	and	N	O
additional	JJ	additional	additional	addit	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
motor	NN	motor	motor	motor	N	O
or	CC	or	or	or	N	O
sensory	JJ	sensory	sensory	sensori	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
unilateral	JJ	unilateral	unilateral	unilater	N	O
or	CC	or	or	or	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
weakness	NN	weakness	weakness	weak	Y	O
,	,	,	,	,	N	O
sensory	JJ	sensory	sensory	sensori	N	O
alterations	NNS	alterations	alteration	alter	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
(	(	(	(	(	N	O
interfering	VBG	interfering	interfering	interf	N	O
with	IN	with	with	with	N	O
daily	JJ	daily	daily	daili	N	O
activities	NNS	activities	activity	activ	N	O
)	)	)	)	)	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Guillain	NNP	guillain	guillain	guillain	N	O
-	:	-	-	-	N	O
Barre	NNP	barre	barre	barr	N	O
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Institute	NNP	institute	institute	institut	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
as	IN	as	a	as	N	O
appropriate	NN	appropriate	appropriate	appropri	N	O
for	IN	for	for	for	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
neuropathies	NNS	neuropathies	neuropathy	neuropathi	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
dosing	VBG	dosing	dosing	dose	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
neuropathy	NNS	neuropathy	neuropathy	neuropathi	Y	O
(	(	(	(	(	N	O
not	RB	not	not	not	N	O
interfering	VBG	interfering	interfering	interf	N	O
with	IN	with	with	with	N	O
daily	JJ	daily	daily	daili	N	O
activities	NNS	activities	activity	activ	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.5	CD	5.5	5.5	5.5	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
severe	FW	severe	severe	sever	N	B-Severity
to	TO	to	to	to	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	I-AdverseReaction
(	(	(	(	(	N	O
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
,	,	,	,	,	N	O
urgent	JJ	urgent	urgent	urgent	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
interfering	VBG	interfering	interfering	interf	N	O
with	IN	with	with	with	N	O
activities	NNS	activities	activity	activ	N	O
of	IN	of	of	of	N	O
daily	JJ	daily	daily	daili	N	O
living	NN	living	living	live	N	O
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
YERVOY	SYM	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
9	CD	9	9	9	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
hypopituitarism	NN	hypopituitarism	hypopituitarism	hypopituitar	Y	B-AdverseReaction
and	CC	and	and	and	N	O
some	DT	some	some	some	N	O
had	VBD	had	had	had	N	O
additional	JJ	additional	additional	addit	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	B-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
,	,	,	,	,	N	O
hypogonadism	NN	hypogonadism	hypogonadism	hypogonad	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
9	CD	9	9	9	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
hospitalized	VBN	hospitalized	hospitalized	hospit	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	B-Severity
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	B-AdverseReaction
.	.	.	.	.	N	O

Moderate	NNP	moderate	moderate	moder	N	B-Severity
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	B-AdverseReaction
(	(	(	(	(	N	O
requiring	VBG	requiring	requiring	requir	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
or	CC	or	or	or	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
;	:	;	;	;	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
consisted	VBN	consisted	consisted	consist	N	O
of	IN	of	of	of	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
,	,	,	,	,	N	O
adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
,	,	,	,	,	N	O
hypopituitarism	NN	hypopituitarism	hypopituitarism	hypopituitar	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
hyperthyroidism	NN	hyperthyroidism	hyperthyroidism	hyperthyroid	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Cushing	NNP	cushing	cushing	cush	N	B-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	B-Severity
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
11	CD	11	11	11	N	O
weeks	NNS	weeks	week	week	N	O
and	CC	and	and	and	N	O
ranged	VBD	ranged	ranged	rang	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
19.3	CD	19.3	19.3	19.3	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
21	CD	21	21	21	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
endocrinopathy	NN	endocrinopathy	endocrinopathy	endocrinopathi	N	B-AdverseReaction
,	,	,	,	,	N	O
17	CD	17	17	17	N	O
patients	NNS	patients	patient	patient	N	O
required	VBN	required	required	requir	N	O
long	RB	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
,	,	,	,	,	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
hormones	NNS	hormones	hormone	hormon	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormones	NNS	hormones	hormone	hormon	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
clinical	JJ	clinical	clinical	clinic	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypophysitis	NN	hypophysitis	hypophysitis	hypophys	Y	O
,	,	,	,	,	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
adrenal	JJ	adrenal	adrenal	adren	N	O
crisis	NN	crisis	crisis	crisi	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hyper	SYM	hyper	hyper	hyper	N	O
-	:	-	-	-	N	O
or	CC	or	or	or	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
present	VB	present	present	present	N	O
with	IN	with	with	with	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	O
,	,	,	,	,	N	O
mental	JJ	mental	mental	mental	N	O
status	NN	status	status	statu	N	O
changes	NNS	changes	change	chang	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
unusual	JJ	unusual	unusual	unusu	N	O
bowel	NN	bowel	bowel	bowel	N	O
habits	NNS	habits	habit	habit	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
nonspecific	NN	nonspecific	nonspecific	nonspecif	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
resemble	VB	resemble	resemble	resembl	N	O
other	JJ	other	other	other	N	O
causes	NNS	causes	cause	caus	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
brain	NN	brain	brain	brain	N	O
metastasis	NN	metastasis	metastasis	metastasi	Y	O
or	CC	or	or	or	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Unless	IN	unless	unless	unless	N	O
an	DT	an	an	an	N	O
alternate	NN	alternate	alternate	altern	N	O
etiology	NN	etiology	etiology	etiolog	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
,	,	,	,	,	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
endocrinopathies	NNS	endocrinopathies	endocrinopathies	endocrinopathi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
clinical	JJ	clinical	clinical	clinic	N	O
chemistries	NNS	chemistries	chemistry	chemistri	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
limited	JJ	limited	limited	limit	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
hypophysitis	NN	hypophysitis	hypophysitis	hypophys	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
by	IN	by	by	by	N	O
imaging	VBG	imaging	imaging	imag	N	O
studies	NNS	studies	study	studi	N	O
through	IN	through	through	through	N	O
enlargement	NN	enlargement	enlargement	enlarg	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
pituitary	JJ	pituitary	pituitary	pituitari	N	O
gland	NN	gland	gland	gland	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
dosing	VBG	dosing	dosing	dose	N	O
in	IN	in	in	in	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Initiate	NNP	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

5.6	CD	5.6	5.6	5.6	N	O
Other	JJ	other	other	other	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
Including	NNP	including	including	includ	N	O
Ocular	NNP	ocular	ocular	ocular	N	O
Manifestations	NNP	manifestations	manifestation	manifest	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
nephritis	NN	nephritis	nephritis	nephriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
meningitis	NN	meningitis	meningitis	mening	Y	B-AdverseReaction
,	,	,	,	,	N	O
pericarditis	NN	pericarditis	pericarditis	pericard	Y	B-AdverseReaction
,	,	,	,	,	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
iritis	NN	iritis	iritis	iriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
for	IN	for	for	for	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
likely	JJ	likely	likely	like	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
incidence	NN	incidence	incidence	incid	N	O
:	:	:	:	:	N	O
myocarditis	NN	myocarditis	myocarditis	myocard	Y	B-AdverseReaction
,	,	,	,	,	N	O
angiopathy	JJ	angiopathy	angiopathy	angiopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
temporal	JJ	temporal	temporal	tempor	N	B-AdverseReaction
arteritis	NN	arteritis	arteritis	arter	Y	I-AdverseReaction
,	,	,	,	,	N	O
vasculitis	NN	vasculitis	vasculitis	vascul	Y	B-AdverseReaction
,	,	,	,	,	N	O
polymyalgia	NN	polymyalgia	polymyalgia	polymyalgia	Y	B-AdverseReaction
rheumatica	NN	rheumatica	rheumatica	rheumatica	N	I-AdverseReaction
,	,	,	,	,	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction
,	,	,	,	,	N	O
blepharitis	NN	blepharitis	blepharitis	blephar	Y	B-AdverseReaction
,	,	,	,	,	N	O
episcleritis	NN	episcleritis	episcleritis	episcler	Y	B-AdverseReaction
,	,	,	,	,	N	O
scleritis	NN	scleritis	scleritis	scleriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukocytoclastic	JJ	leukocytoclastic	leukocytoclastic	leukocytoclast	N	B-AdverseReaction
vasculitis	NN	vasculitis	vasculitis	vascul	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
,	,	,	,	,	N	O
psoriasis	NN	psoriasis	psoriasis	psoriasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthritis	NN	arthritis	arthritis	arthriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
autoimmune	JJ	autoimmune	autoimmune	autoimmun	N	B-AdverseReaction
thyroiditis	NN	thyroiditis	thyroiditis	thyroid	Y	I-AdverseReaction
,	,	,	,	,	N	O
sarcoidosis	NN	sarcoidosis	sarcoidosis	sarcoidosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
neurosensory	JJ	neurosensory	neurosensory	neurosensori	N	B-AdverseReaction
hypoacusis	NN	hypoacusis	hypoacusis	hypoacusi	Y	I-AdverseReaction
,	,	,	,	,	N	O
autoimmune	JJ	autoimmune	autoimmune	autoimmun	N	B-AdverseReaction
central	JJ	central	central	central	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
encephalitis	NN	encephalitis	encephalitis	enceph	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
myositis	NN	myositis	myositis	myositi	Y	B-AdverseReaction
,	,	,	,	,	N	O
polymyositis	NN	polymyositis	polymyositis	polymyos	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ocular	JJ	ocular	ocular	ocular	N	B-AdverseReaction
myositis	NN	myositis	myositis	myositi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
for	IN	for	for	for	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	JJ	mediated	mediated	mediat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Initiate	NNP	initiate	initiate	initi	N	O
systemic	JJ	systemic	systemic	system	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
day	NN	day	day	day	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
equivalent	NN	equivalent	equivalent	equival	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	JJ	mediated	mediated	mediat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
eye	NN	eye	eye	eye	N	O
drops	NNS	drops	drop	drop	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
uveitis	NN	uveitis	uveitis	uveiti	Y	O
,	,	,	,	,	N	O
iritis	NN	iritis	iritis	iriti	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
episcleritis	NN	episcleritis	episcleritis	episcler	Y	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBZ	discontinue	discontinue	discontinu	N	O
YERVOY	NNP	yervoy	yervoy	yervoy	N	O
for	IN	for	for	for	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
ocular	JJ	ocular	ocular	ocular	N	O
disease	NN	disease	disease	diseas	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
unresponsive	JJ	unresponsive	unresponsive	unrespons	N	O
to	TO	to	to	to	N	O
local	JJ	local	local	local	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

